OPKO Health stock (US68375N1037): Genomics leader with recent subsidiary activity

OPKO Health, parent of GeneDx, shows market cap over $1B amid biotech volatility. GeneDx shares ranged $32-$170 recently, per MarketBeat data.

OPKO Health maintains a strong presence in diagnostics through its GeneDx subsidiary, which specializes in genetic testing for rare disorders. GeneDx became a subsidiary in 2015, utilizing OPKO's infrastructure for expansion. Recent trading data highlights GeneDx (WGS) with a market capitalization of $1.17 billion and a 52-week range from $32.21 to $170.87, according to MarketBeat as of May 2026. This reflects ongoing volatility in the genomics sector relevant to US investors tracking Nasdaq-listed biotechs.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: OPKO Health, Inc.
• Sector/industry: Diagnostics and biotechnology
• Headquarters/country: United States
• Core markets: US and global
• Key revenue drivers: Genetic testing, point-of-care diagnostics
• Home exchange/listing venue: Nasdaq (OPK)
• Trading currency: USD

OPKO Health: core business model

OPKO Health operates in diagnostics and pharmaceuticals, with a focus on genomics and rare disease testing via GeneDx. The company leverages proprietary technologies for genetic sequencing and analysis, serving healthcare providers worldwide. Historical data is available on its investor site, showing stock performance over years, per OPKO Health investor page as of May 2026. This model positions OPKO in the growing personalized medicine market.

Subsidiaries like GeneDx drive innovation in clinical diagnostics, expanding testing capabilities since 2015 through OPKO's global network. The structure supports research collaborations and scalable operations, key for US investors eyeing biotech exposure on Nasdaq.

Main revenue and product drivers for OPKO Health

Primary revenue stems from genetic and genomic testing, particularly for inherited disorders. GeneDx offers comprehensive panels, contributing significantly to OPKO's diagnostics segment. Products include point-of-care tests and biopharmaceuticals, with partnerships enhancing distribution, such as deals involving OPKO Health Europe products noted in recent filings.

Affiliates like Non-Invasive Monitoring Systems reference OPKO's involvement, though NIMU reported Q1 2026 losses as a shell entity, per StockTitan on Q1 2026 results. Core drivers remain robust in genomics amid US healthcare demand.

Industry trends and competitive position

The genomics sector sees rising demand for precision diagnostics, benefiting OPKO Health's offerings. Competitors include Illumina and smaller gene testing firms, but OPKO's integrated model via subsidiaries provides edge in rare disease focus. US market leadership in clinical genomics underscores relevance for domestic investors.

Why OPKO Health matters for US investors

Listed on Nasdaq as OPK, OPKO offers exposure to biotech innovation with US headquarters and heavy reliance on American healthcare spending. GeneDx's testing volumes tie into Medicare and private insurance trends, making it a watchpoint for portfolios tracking medical tech growth.

Conclusion

OPKO Health continues leveraging its GeneDx unit in the competitive genomics field, with recent subsidiary trading data signaling market interest. While filings note affiliate challenges, core diagnostics remain a pillar. US investors monitor Nasdaq performance for biotech trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.